Asheville VA Selected for National Clinical Trial Evaluating Semaglutide as a Treatment for Alcohol Use Disorder
By Marge Farrington | Published 2026-08-02T16:52:37.459Z
News
Asheville -- August 2, 2026: The Charles George Department of Veterans Affairs Medical Center in Asheville has been selected as one of 18 U.S. Department of Veterans Affairs medical centers participating in a nationwide clinical trial evaluating whether semaglutide, a medication commonly used to treat Type 2 diabetes and obesity, could become a new treatment option for alcohol use disorder (AUD).
Asheville -- August 2, 2026: The Charles George Department of Veterans Affairs Medical Center in Asheville has been selected as one of 18 U.S. Department of Veterans Affairs medical centers participating in a nationwide clinical trial evaluating whether semaglutide, a medication commonly used to treat Type 2 diabetes and obesity, could become a new treatment option for alcohol use disorder (AUD).The study, known as the Cessation or Reduction of Alcohol Consumption in Veterans (CRAVE) trial, is